At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular complications.

Our analysis highlights that elevated non-invasive tests for liver steatosis and fibrosis are strongly associated with a heightened risk of major adverse cardiovascular events (MACE). Importantly, the study also showed that bempedoic acid significantly reduces MACE risk, particularly in patients with high steatosis scores on non-invasive tests.

These findings underscore the potential of non-invasive liver tests to identify patients at the greatest risk for cardiovascular events. They also emphasize the importance of early cardiovascular management in patients with MASLD, offering a proactive approach to reducing risk and improving outcomes.

By bridging insights from liver and cardiovascular health, this analysis could pave the way for more targeted and effective interventions for high-risk patients.

Outcomes of the CLEAR study: